Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease.

Gisondi, Paolo; Geat, Davide; Maurelli, Martina; Degli Esposti, Luca; Bellinato, Francesco; Girolomoni, Giampiero

Gisondi, Paolo; Geat, Davide; Maurelli, Martina; Degli Esposti, Luca; Bellinato, Francesco; Girolomoni, Giampiero.

Afiliación

Gisondi P; Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.
Geat D; Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.
Maurelli M; Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.
Degli Esposti L; CliCon S.r.l. Health, Economics & Outcomes Research, 40121 Bologna, Italy.
Bellinato F; Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.
Girolomoni G; Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.

Vaccines (Basel) ; 10(5)2022 Apr 20.

Article en En | MEDLINE | ID: mdl-35632402

Palabras clave

adalimumab; cost per responder; secukinumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google